Navigation Links
Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Date:4/23/2008

EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that Dr. Jie Lu and Dr. Zhengping Zhuang of the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and its collaborator, Lixte Biotechnology Holdings. Inc., reported at the Annual Meeting of the American Association of Cancer Research that its lead compound LB-1, one of a patent-pending proprietary series of agents, has anti-cancer activity against human glioblastoma multiforme cells in a mouse model of cancer. Glioblastoma multiforme is the most common and aggressive brain tumor of adults.

The Dr. John S. Kovach, President and CEO of Lixte, said that the company and SNB, NINDS are continuing to develop LB-1 and analogs of the compound for the treatment of human brain cancers. Brain cancers pose a particular challenge to the development of effective drug treatments. The brain is protected by a physiological barrier that prevents the entry of many compounds from the blood into brain tissue. To be effective, drugs must be designed either to pass this barrier or be administered directly into the brain. "We are pursuing both strategies for the treatment of glioblastoma multiforme in a rat model in which the cancer is growing in the brain," said Dr. Kovach. "We want to be certain that we achieve drug delivery into the brain at concentrations that inhibit these tumors."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):

NINDS (http://www.ninds.nih.gov) is a component of
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 Legislation passed today by ... provision to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA) of 2014 , ... Kevin Brady (R-TX) and Ranking Member Jim McDermott ... abuse epidemic and implement the right policies, said the ...
(Date:2/26/2015)... February 26, 2015 LifeScienceIndustryResearch.com ... First -In- Class Innovations and Cost Optimization Plays ... Cap Pharmaceutical Companies research report to the pharmaceuticals ... to this Global Pharma US & EU Outlook ... measurements, divestment of non-core assets result in healthy ...
(Date:2/26/2015)...  BD Life Sciences, a segment of BD ... ), a leading global medical technology company, and ... high-resolution biology, today announced that they will be ... cell isolation and single-cell gene expression analysis. ... FACS™ single-cell sorting instrumentation and software with Cellular ...
Breaking Medicine Technology:PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3
... SAN FRANCISCO, June 6 OxyBand Technologies Inc., ... the company,s bio-medical,technology development and expand the company,s ... for,health, cosmetic and consumer care. The company,s inaugural ... the FDA for medical and over the,counter marketing. ...
... Data Indicate Overall and Disease-Free Survival -, ... adjuvant trial in,high-risk melanoma patients demonstrated that a ... and/or overall,survival. These findings, which indicate Leukine,s potential ... annual meeting of the American Society,of Clinical Oncology ...
Cached Medicine Technology:OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 3Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 4Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 5
(Date:2/27/2015)... MA (PRWEB) February 27, 2015 ... mobility management services, and one of the ... announced support for Bell Mobility within their CLEAN ... of services. Wireless Analytics’ newly developed Bell ... reporting for the Canadian wireless carrier’s business customers. ...
(Date:2/27/2015)... 2015 A new study published in ... men who cycle on a regular basis and prostate cancer. ... suggests that the more hours per week a man spends ... leading to an increased importance on prostate cancer screening methods. ... look more closely at patents’ risk factors for developing prostate ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... “cutters”, are often misunderstood, misdiagnosed and therefore ... to healthy lives. Jacksonville-based addiction treatment ... of its highly acclaimed Lakeview Professional Lecture ... interested in understanding this complicated condition. ...
(Date:2/27/2015)... On March 2-4, the Mesothelioma ... Cancer Institute (NCI) will co-host the annual International ... of Health (NIH), in Bethesda, Maryland. The event ... medical professionals and scientists who specialize in mesothelioma, ... public, including patients, their families, and caregivers. , ...
(Date:2/27/2015)... Altec Products, Inc., announced today that ... as their doc-link for Dynamics Partner of the Year. ... solutions for their customers in all different industries with ... and BPW have worked side-by-side to successfully help clients ... , “We are so impressed by the success that ...
Breaking Medicine News(10 mins):Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... ATS 2008, TORONTOXScientists believe they may have identified a ... risk of allergy and asthma in childhood. They will ... International Conference in Toronto on Tuesday, May 20., Several ... without allergy at the time of birth. For example, ...
... 21 The Quantum Group,Inc. (Amex: QGP, QGP.WSA, QGP.WSB) ... successfully completed a corporate expansion plan. The Company,increased its ... facility size from 6,600 sq. ft. to 10,600 sq. ... to a larger facility in Doral (west,Miami), Florida., ...
... 21 Crdentia Corp. (OTC Bulletin,Board: CRDT), a leading ... ended March 31, 2008., Revenue in the quarter ... revenue of $9,806,540 and an increase of 31% over ... profit improved to,$2,310,854 in the first quarter of 2008, ...
... ACM today announced a new strategic,alignment that ... next generation technology and services to the two ... commercial plans and,payers, and federal and state governments., ... has been,named EVP/General Manager for Government, and will ...
... sleep apnea (OSA) in very young children may cause ... older children and adults with the condition, according to ... the American Thoracic Societys 2008 International Conference in Toronto ... year of life, said Aviv Goldbart, M.D., the pediatric ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
Cached Medicine News:Health News:Possible biological explanation for C-Section-linked allergies and asthma found 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:Crdentia Announces 2008 First Quarter Results 2Health News:Crdentia Announces 2008 First Quarter Results 3Health News:Crdentia Announces 2008 First Quarter Results 4Health News:Crdentia Announces 2008 First Quarter Results 5Health News:Crdentia Announces 2008 First Quarter Results 6Health News:Crdentia Announces 2008 First Quarter Results 7Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2
... are designed with the clinician in mind. ... be removed to simplify cleaning - no ... unique snap-on mechanism eliminates screws that can ... interchangeable with other green coded fiber optic ...
Rigid plastic. Single use. Non-Sterile. The disposable laryngoscope blade that fits on a standard handle. Made of extremely rigid plastic. Bright white light out-performs metal blades. Single patient...
Rigid plastic. Single use. Non-Sterile. The disposable laryngoscope blade that fits on a standard handle. Made of extremely rigid plastic. Bright white light out-performs metal blades. Single patient...
... a unique fiberoptic laryngoscope blade that can ... sometimes needed during difficult intubations. The articulating ... blade to be raised by squeezing a ... operation produces a more complete exposure of ...
Medicine Products: